Why must the protocol describe dosing schedules and follow-up periods for each treatment group?

• A. To allow flexible dosing at investigators' discretion
• B. To ensure consistent administration and data collection across arms
• C. To minimize regulatory oversight
• D. To simplify data analysis

Answer: (B)

Dosing schedules and follow-up periods are defined to ensure uniformity in both how treatments are given and how outcomes are assessed across all arms. This standardization reduces variability that isn’t due to the treatments themselves, making it possible to attribute any differences in outcomes to the therapies being tested rather than to differences in dosing timing or measurement.

It also supports consistent safety monitoring and data collection, so adverse events and efficacy outcomes are captured at the same times relative to treatment across groups. That consistency is essential for valid comparisons, preserving study power, and meeting regulatory and data integrity expectations.

Flexible dosing or inconsistent follow-up would introduce bias and confounding, making it harder to determine true treatment effects. It wouldn’t simplify regulatory oversight or data analysis; rather, it undermines reliability by allowing differences in administration and assessment methods across arms.